Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...